Biomarker panel of cardiac and skeletal muscle troponins, fatty acid binding protein 3 and myosin light chain 3 for the accurate diagnosis of cardiotoxicity and musculoskeletal toxicity in rats

Toxicology

Volumn 302, Issue 2-3, 2012, Pages 179-189

  Tonomura, Yutaka ^a,b   Matsushima, Shuuichi ^a   Kashiwagi, Emi ^a   Fujisawa, Kae ^a   Takagi, Shingo ^a   Nishimura, Yoko ^a   Fukushima, Ryou ^a   Torii, Mikinori ^a   Matsubara, Mitsunobu ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiac troponin I; Cardiac troponin T; Fatty acid binding protein 3; Myosin light chain 3; Myotoxicity; Skeletal muscle troponin I

Indexed keywords

1 NAPHTHYL ISOTHIOCYANATE; ALLYL ALCOHOL; ALLYLAMINE; AMINOGLUTETHIMIDE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 3; ISOPRENALINE; LACTATE DEHYDROGENASE; METHAPYRILENE; MITOXANTRONE; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 3; ORCIPRENALINE; PARACETAMOL; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FABP3 PROTEIN, RAT; TROPONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAPHRAGM MUSCLE; GASTROCNEMIUS MUSCLE; HEART MUSCLE; HEART MUSCLE NECROSIS; HISTOPATHOLOGY; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG MUSCLE; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL TOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIVITY AND SPECIFICITY; SKELETAL MUSCLE; SOLEUS MUSCLE; TISSUE DISTRIBUTION; ANIMAL; HEART DISEASE; METABOLISM; MUSCLE DISEASE; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CREATINE KINASE; FATTY ACID-BINDING PROTEINS; HEART DISEASES; L-LACTATE DEHYDROGENASE; MALE; MUSCLE, SKELETAL; MUSCULAR DISEASES; MYOCARDIUM; MYOSIN LIGHT CHAINS; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TROPONIN;

EID: 84897120310     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.07.012     Document Type: Article

References (48)

1. Berthiaume, J.M., Wallace, K.B., 2007. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 23, 15-25.
2. Brenner, B.M., Beeuwkes, R., 1978. The renal circulations. Hosp. Pract. 13, 35-46.
3. Clements, P., Brady, S., York, M., Berridge, B., Mikaelian, I., Nicklaus, R., Gandhi, M., Roman, I., Stamp, C., Davies, D., McGill, P., Williams, T., Pettit, S., Walker, D., ILSI HESI Cardiac Troponins Working Group, Turton, J., 2010. Time course characterization of serum cardiac troponins, heart fatty acid-binding protein, and morphologic findings with isoproterenol-induced myocardial injury in the rat. Toxicol. Pathol. 38, 703-714.
4. Colli, A., Josa, M., Pomar, J.L., Mestres, C.A., Gherli, T., 2007. Heart fatty acid binding protein in the diagnosis of myocardial infarction: where do we stand today? Cardiology 108, 4-10.
5. D'Amico, G., Bazzi, C., 2003. Pathophysiology of proteinuria. Kidney Int. 63, 809-825.
6. Dieterle, F., Perentes, E., Cordier, A., Roth, D.R., Verdes, P., Grenet, O., Pantano, S., Moulin, P., Wahl, D., Mahl, A., End, P., Staedtler, F., Legay, F., Carl, K., Laurie, D., Chibout, S.D., Vonderscher, J., Maurer, G., 2010. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat. Biotechnol. 28, 463-469.
7. Engle, S.K., Jordan, W.H., Pritt, M.L., Chiang, A.Y., Davis, M.A., Zimmermann, J.L., Rudmann, D.G., Heinz-Taheny, K.M., Irizarry, A.R., Yamamoto, Y., Mendel, D., Schultze, A.E., Cornwell, P.D., Watson, D.E., 2009. Qualification of cardiac troponin I concentration in mouse serum using isoproterenol and implementation in pharmacology studies to accelerate drug development. Toxicol. Pathol. 37, 617-628.
8. Frank, J.J., Bermes, E.W., Bickel, M.J., Watkins, B.F., 1978. Effect of in vitro hemolysis on chemical values for serum. Clin. Chem. 24, 1966-1970.
9. Furberg, C.D., Pitt, B., 2001. Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc. Med. 2, 205-207.
10. Giannitsis, E., Steen, H., Kurz, K., Ivandic, B., Simon, A.C., Futterer, S., Schild, C., Isfort, P., Jaffe, A.S., Katus, H.A., 2008. Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single time-point measurements of cardiac troponin T. J. Am. Coll. Cardiol. 51, 307-314.
11. Hassan, A.K., Bergheanu, S.C., Hasan-Ali, H., Liem, S.S., van der Laarse, A., Wolterbeek, R., Atsma, D.E., Schalij, M.J., Jukema, J.W. 2009. Usefulness of peak troponin-T to predict infarct size and long-term outcome in patients with first acute myocardial infarction after primary percutaneous coronary intervention. Am. J. Cardiol. 103, 779-784.
12. Haynes, C.M., Titus, E.A., Cooper, A.A., 2004. Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol. Cell 15, 767-776.
13. Hickman, P.E., Potter, J.M., Aroney, C., Koerbin, G., Southcott, E., Wu, A.H., Roberts, M.S., 2010. Cardiac troponin may be released by ischemia alone, without necrosis. Clin. Chim. Acta 411, 318-323.
14. Hillis, G.S., Taggart, P., Hillis, L., Zhao, N., Dalsey, W.C., Mangione, A., 2003. Biochemical and clinical predictors of long-term outcome in patients with nonspecific chest pain and nondiagnostic electrocardiograms. Am. Heart J. 145, 88-94.
15. Hoffman, W.E., Wilson, B.W., Solter, P.F., 1999. Clinical enzymology. In: Loeb, W.F., Quimby, F.W. (Eds.), The Clinical Chemistry of Laboratory Animals. Taylor and Francis, pp. 399-454.
16. Keller, T., Zeller, T., Peetz, D., Tzikas, S., Roth, A., Czyz, E., Bickel, C., Baldus, S., Warnholtz, A., Fröhlich, M., Sinning, C.R., Eleftheriadis, M.S., Wild, P.S., Schnabel, R.B., Lubos, E., Jachmann, N., Genth-Zotz, S., Post, F., Nicaud, V., Tiret, L., Lackner, K.J., Münzel, T.F., Blankenberg, S., 2009. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N. Engl. J. Med. 361, 868-877.
17. Koppe, R.I., Hallauer, P.L., Karpati, G., Hastings, K.E., 1989. cDNA clone and expression analysis of rodent fast and slow skeletal muscle troponin I mRNAs. J. Biol. Chem. 264, 14327-14333.
18. Labugger, R., Organ, L., Collier, C., Atar, D., Van Eyk, J.E., 2000. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 102, 1221-1226.
19. Leonard, T.B., Neptun, D.A., Popp, J.A., 1984. Serum gamma glutamyl transferase as a specific indicator of bile duct lesions in the rat liver. Am. J. Pathol. 116, 262-269.
20. Liu, X., Yu, X., Zack, D.J., Zhu, H., Qian, J., 2008. TiGER: a database for tissue-specific gene expression and regulation. BMC Bioinform. 9, 271.
21. Matziolis, D., Wassilew, G., Strube, P., Matziolis, G., Perka, C., 2011. Differences in muscle trauma quantifiable in the laboratory between the minimally invasive anterolateral and transgluteal approach. Arch. Orthop. Trauma Surg. 131, 651-655.
22. Murphy, A.M., Jones 2nd., L., Sims, H.F., Strauss, A.W. 1991. Molecular cloning of rat cardiac troponin I and analysis of troponin I isoform expression in developing rat heart. Biochemistry 30, 707-712.
23. Nelson, T.J., Boor, P.J., 1982. Allylamine cardiotoxicity. IV. Metabolism to acrolein by cardiovascular tissues. Biochem. Pharmacol. 31, 509-514.
24. O'Brien, P.J., Dameron, G.W., Beck, M.L., Kang, Y.J., Erickson, B.K., Di Battista, T.H., Miller, K.E., Jackson, K.N., Mittelstadt, S., 1997. Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab. Anim. Sci. 47, 486-495.
25. O'Brien, P.J., Smith, D.E., Knechtel, T.J., Marchak, M.A., Pruimboom-Brees, I., Brees, D.J., Spratt, D.P., Archer, F.J., Butler, P., Potter, A.N., Provost, J.P., Richard, J., Snyder, P.A., Reagan, W.J., 2006. Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab. Anim. 40, 153-171.
26. O'Brien, P.J., 2008. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 245, 206-218.
27. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., Van Deun, K., Smith, P., Berger, B., Heller, A., 2000. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67.
28. Ozer, J.S., Dieterle, F., Troth, S., Perentes, E., Cordier, A., Verdes, P., Staedtler, F., Mahl, A., Grenet, O., Roth, D.R., Wahl, D., Legay, F., Holder, D., Erdos, Z., Vlasakova, K., Jin, H., Yu, Y., Muniappa, N., Forest, T., Clouse, H.K., Reynolds, S., Bailey, W.J., Thudium, D.T., Topper, M.J., Skopek, T.R., Sina, J.F., Glaab, W.E., Vonderscher, J., Maurer, G., Chibout, S.D., Sistare, F.D., Gerhold, D.L., 2010. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat. Biotechnol. 28, 486-494.
29. Paulussen, R.J., Geelen, M.J., Beynen, A.C., Veerkamp, J.H., 1989. Immunochemical quantitation of fatty-acid-binding proteins. I. Tissue and intracellular distribution, postnatal development and influence of physiological conditions on rat heart and liver FABP. Biochim. Biophys. Acta 1001, 201-209.
30. Pelsers, M.M., Hermens, W.T., Glatz, J.F., 2005. Fatty acid-binding proteins as plasma markers of tissue injury. Clin. Chim. Acta 352, 15-35.
31. Periasamy, M., Wadgaonkar, R., Kumar, C., Martin, B.J., Siddiqui, M.A., 1989. Characterization of a rat myosin alkali light chain gene expressed in ventricular and slow twitch skeletal muscles. Nucleic Acids Res. 17, 7723-7734.
32. Pritt, M.L., Hall, D.G., Recknor, J., Credille, K.M., Brown, D.D., Yumibe, N.P., Schultze, A.E., Watson, D.E., 2008. Fabp3 as a biomarker of skeletal muscle toxicity in the rat: comparison with conventional biomarkers. Toxicol. Sci. 103, 382-396.
33. Qureshi, Z.P., Seoane-Vazquez, E., Rodriguez-Monguio, R., Stevenson, K.B., Szeinbach, S.L., 2011. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol. Drug Saf. 20, 772-777.
34. Ravkilde, J., Nissen, H., Hørder, M., Thygesen, K., 1995. Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction. Analysis of 28 months of follow-up in 196 patients. J. Am. Coll. Cardiol. 25, 574-581.
35. Reichlin, T., Hochholzer, W., Bassetti, S., Steuer, S., Stelzig, C., Hartwiger, S., Biedert, S., Schaub, N., Buerge, C., Potocki, M., Noveanu, M., Breidthardt, T., Twerenbold, R., Winkler, K., Bingisser, R., Mueller, C., 2009. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N. Engl. J. Med. 361, 858-867.
36. Rezzani, R., 2006. Exploring cyclosporine A-side effects and the protective role-played by antioxidants: the morphological and immunohistochemical studies. Histol. Histopathol. 21, 301-316.
37. Rona, G., Chappel, C.I., Balazs, T., Gaudy, R., 1959. An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. AMA Arch. Pathol. 67, 443-455.
38. Santen, R.J., Misbin, R.I., 1981. Aminoglutethimide: review of pharmacology and clinical use. Pharmacotherapy 1, 95-120.
39. Simpson, J.A., Labugger, R., Collier, C., Brison, R.J., Iscoe, S., Van Eyk, J.E., 2005. Fast and slow skeletal troponin I in serum from patients with various skeletal muscle disorders: a pilot study. Clin. Chem. 51, 966-972.
40. Sistare, F.D., Dieterle, F., Troth, S., Holder, D.J., Gerhold, D., Andrews-Cleavenger, D., Baer, W., Betton, G., Bounous, D., Carl, K., Collins, N., Goering, P., Goodsaid, F., Gu, Y.Z., Guilpin, V., Harpur, E., Hassan, A., Jacobson-Kram, D., Kasper, P., Laurie, D., Lima, B.S., Maciulaitis, R., Mattes, W., Maurer, G., Obert, L.A., Ozer, J., Papaluca-Amati, M., Phillips, J.A., Pinches, M., Schipper, M.J., Thompson, K.L., Vamvakas, S., Vidal, J.M., Vonderscher, J., Walker, E., Webb, C., Yu, Y., 2010. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat. Biotechnol. 28, 446-454.
41. Sladek, N.E., 1988. Metabolism of oxazaphosphorines. Pharmacol. Ther. 37, 301-355.
42. Takahashi, M., Lee, L., Shi, Q., Gawad, Y., Jackowski, G., 1996. Use of enzyme immunoassay for measurement of skeletal troponin-I utilizing isoform-specific monoclonal antibodies. Clin. Biochem. 29, 301-308.
43. Tonomura, Y., Mori, Y., Torii, M., Uehara, T., 2009. Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats. Toxicology 266, 48-54.
44. Toraason, M., Luken, M.E., Breitenstein, M., Krueger, J.A., Biagini, R.E., 1989. Comparative toxicity of allylamine and acrolein in cultured myocytes and fibroblasts from neonatal rat heart. Toxicology 56, 107-117.
45. Vassallo, J.D., Janovitz, E.B., Wescott, D.M., Chadwick, C., Lowe-Krentz, L.J., Lehman-McKeeman, L.D., 2009. Biomarkers of drug-induced skeletal muscle injury in the rat: troponin I and myoglobin. Toxicol. Sci. 111, 402-412.
46. Wang, G., Yeh, H.I., Lin, J.J., 1994. Characterization of cis-regulating elements and trans-activating factors of the rat cardiac troponin T gene. J. Biol. Chem. 269, 30595-30603.
47. Yamaura, Y., Nakajima, M., Takagi, S., Fukami, T., Tsuneyama, K., Yokoi, T., 2012. Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS One 7, e30250.
48. Ziebig, R., Lun, A., Hocher, B., Priem, F., Altermann, C., Asmus, G., Kern, H., Krause, R., Lorenz, B., Möbes, R., Sinha, P., 2003. Renal elimination of troponin T and troponin I. Clin. Chem. 49, 1191-1193.